John G. Geisler, PhD, is the founder and chief scientific officer at Mitochon Pharmaceuticals, Inc. Dr. Geisler has expertise in drug discovery in metabolic disease (Pfizer, Ionis, JnJ), with a primary role of bringing forward the inception of new ideas. Following many years of research, Dr. Geisler built an expertise in mitochondrial (powerhouse of the cell) energy expenditure; from this work also stemmed a broader understanding of new mitochondrial-targeted applications and pharmacological interventions for movement disorders and neurodegenerative diseases. Dr. Geisler holds a PhD in mammalian genetics from the University of Tennessee, which he conducted at Oak Ridge National Laboratories, and completed a fellowship at Yale University in physiology. Dr. Geisler launched Mitochon Pharmaceuticals in November 2014 with co-founder, Robert Alonso; the company is now clinically staged.